WO2002096455A3 - Verwendung von polyklonalen immunglobulinen als impfstoff - Google Patents

Verwendung von polyklonalen immunglobulinen als impfstoff Download PDF

Info

Publication number
WO2002096455A3
WO2002096455A3 PCT/AT2002/000088 AT0200088W WO02096455A3 WO 2002096455 A3 WO2002096455 A3 WO 2002096455A3 AT 0200088 W AT0200088 W AT 0200088W WO 02096455 A3 WO02096455 A3 WO 02096455A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunising
preparation
immunoglobulins
polyclonal immunoglobulins
allergies
Prior art date
Application number
PCT/AT2002/000088
Other languages
English (en)
French (fr)
Other versions
WO2002096455A2 (de
Inventor
Hans Loibner
Gottfried Himmler
Original Assignee
Igeneon Krebs Immuntherapie
Hans Loibner
Gottfried Himmler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0210239-0A priority Critical patent/BR0210239A/pt
Priority to EP02707990A priority patent/EP1399185A2/de
Priority to IL15895002A priority patent/IL158950A0/xx
Priority to JP2002592964A priority patent/JP2004532261A/ja
Application filed by Igeneon Krebs Immuntherapie, Hans Loibner, Gottfried Himmler filed Critical Igeneon Krebs Immuntherapie
Priority to HU0400031A priority patent/HUP0400031A3/hu
Priority to AU2002242447A priority patent/AU2002242447B2/en
Priority to CA002449026A priority patent/CA2449026A1/en
Priority to MXPA03010829A priority patent/MXPA03010829A/es
Priority to SK1466-2003A priority patent/SK14662003A3/sk
Priority to US10/478,942 priority patent/US20040151717A1/en
Priority to PL02367835A priority patent/PL367835A1/xx
Publication of WO2002096455A2 publication Critical patent/WO2002096455A2/de
Priority to IL158950A priority patent/IL158950A/en
Priority to NO20035282A priority patent/NO20035282L/no
Publication of WO2002096455A3 publication Critical patent/WO2002096455A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Beschrieben wird die Verwendung einer polyklonalen Immunglobulin-präparation zur Herstellung einer Impfstoff-Formulierung, enthaltend Antikörper unterschiedlicher Spezifitäten, zur Immunisierung von Individuen der gleichen Spezies, aus denen die Immunglobuline stammen. Diese aktiv immunisierende Präparation kann beispielsweise zur Prophylaxe oder Behandlung von Krebs, autoimmunerkrankungen, Allergien oder von Infektionsanfälligkeit gegnüber viralen, bakteriellen oder Pilz-Infektionen verwendet werden.
PCT/AT2002/000088 2001-06-01 2002-03-19 Verwendung von polyklonalen immunglobulinen als impfstoff WO2002096455A2 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU2002242447A AU2002242447B2 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins
IL15895002A IL158950A0 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins
JP2002592964A JP2004532261A (ja) 2001-06-01 2002-03-19 ポリクローナル免疫グロブリンの使用
MXPA03010829A MXPA03010829A (es) 2001-06-01 2002-03-19 Uso de inmunoglobulinas policlonales.
HU0400031A HUP0400031A3 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins
EP02707990A EP1399185A2 (de) 2001-06-01 2002-03-19 Verwendung von polyklonalen immunglobulinen als impfstoff
CA002449026A CA2449026A1 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins
BR0210239-0A BR0210239A (pt) 2001-06-01 2002-03-19 Uso de imunoglobinas policlonais e vacina
SK1466-2003A SK14662003A3 (sk) 2001-06-01 2002-03-19 Použitie polyklonálnych imunoglobulínov
US10/478,942 US20040151717A1 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins
PL02367835A PL367835A1 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins as vaccine
IL158950A IL158950A (en) 2001-06-01 2003-11-19 Use of polyclonal immunoglobulins for producing a vaccine
NO20035282A NO20035282L (no) 2001-06-01 2003-11-27 Anvendelse av polyklonale immunglobuliner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA860/2001 2001-06-01
AT0086001A AT410637B (de) 2001-06-01 2001-06-01 Verwendung von polyklonalen immunglobulinen

Publications (2)

Publication Number Publication Date
WO2002096455A2 WO2002096455A2 (de) 2002-12-05
WO2002096455A3 true WO2002096455A3 (de) 2003-12-24

Family

ID=3682339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2002/000088 WO2002096455A2 (de) 2001-06-01 2002-03-19 Verwendung von polyklonalen immunglobulinen als impfstoff

Country Status (16)

Country Link
US (1) US20040151717A1 (de)
EP (1) EP1399185A2 (de)
JP (1) JP2004532261A (de)
CN (1) CN1512895A (de)
AT (1) AT410637B (de)
AU (1) AU2002242447B2 (de)
BR (1) BR0210239A (de)
CA (1) CA2449026A1 (de)
CZ (1) CZ20033273A3 (de)
HU (1) HUP0400031A3 (de)
IL (2) IL158950A0 (de)
MX (1) MXPA03010829A (de)
NO (1) NO20035282L (de)
PL (1) PL367835A1 (de)
SK (1) SK14662003A3 (de)
WO (1) WO2002096455A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10127712A1 (de) * 2001-06-07 2002-12-19 Torsten Witte Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis
EP1664119A1 (de) * 2003-09-08 2006-06-07 Medical Research Council Vehrfahren zur behandlung von oder prophylaxe gegen tuberkulose
US20180264111A1 (en) * 2014-12-03 2018-09-20 Csl Behring Gmbh Ag Pharmaceutical product with increased stability comprising immunoglobulins
FR3072880A1 (fr) * 2017-10-30 2019-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Formulation liposomale et son utilisation en therapie anti-tumorale

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3340487A1 (de) * 1983-11-09 1985-05-15 Sandoz-Patent-GmbH, 7850 Lörrach Neue therapeutische verwendung
WO1992014490A1 (en) * 1991-02-25 1992-09-03 Innovet, Inc. Composition and method for immunostimulation in mammals
WO2001035989A2 (de) * 1999-11-16 2001-05-25 Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag Verwendung von anti-idiotypische antikörpern als impfstoffe gegenkrebs
WO2002080966A2 (de) * 2001-03-23 2002-10-17 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag Verfahren zur herstellung eines autologen antikörpers enthaltenden impfstoffes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG46445A1 (en) * 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP2795289B2 (ja) * 1990-09-04 1998-09-10 富士通株式会社 電子機器におけるプリント板ユニットの保持構造
WO1992015885A1 (en) * 1991-03-11 1992-09-17 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
US5562902A (en) * 1994-03-14 1996-10-08 Arp Biomed, Inc. Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin
TWI248819B (en) * 1999-09-27 2006-02-11 Arp Biomed Ltd Pharmaceutical composition containing IVIG for use in treating lymphoma
AU2001268561A1 (en) * 2000-06-15 2001-12-24 Millennium Pharmaceuticals, Inc. 22109, a novel human thioredoxin family member and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3340487A1 (de) * 1983-11-09 1985-05-15 Sandoz-Patent-GmbH, 7850 Lörrach Neue therapeutische verwendung
WO1992014490A1 (en) * 1991-02-25 1992-09-03 Innovet, Inc. Composition and method for immunostimulation in mammals
WO2001035989A2 (de) * 1999-11-16 2001-05-25 Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag Verwendung von anti-idiotypische antikörpern als impfstoffe gegenkrebs
WO2002080966A2 (de) * 2001-03-23 2002-10-17 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag Verfahren zur herstellung eines autologen antikörpers enthaltenden impfstoffes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAR-DAYAN YARON ET AL: "Antibodies to the cytoplasm, cell membrane and nuclear membrane of malignant neoplasms in pooled normal human polyspecific immunoglobulin G.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 15, no. 6, December 1999 (1999-12-01), pages 1091 - 1096, XP009011084, ISSN: 1019-6439 *
KANIK KEITH S ET AL: "Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis.", ARTHRITIS & RHEUMATISM, vol. 39, no. 6, 1996, pages 1027 - 1029, XP009011083, ISSN: 0004-3591 *
SANDLER BELLA ET AL: "Vaccination with polyclonal non-tumor-specific IgG has no therapeutic effects on tumorigenic activity of hepatoma cells grafted to rats: Experimental and biochemical studies.", ANTICANCER RESEARCH, vol. 19, no. 5B, 1999, pages 4285 - 4288, XP009011062, ISSN: 0250-7005 *
WASFIE T ET AL: "PRODUCTION OF ANTIIDIOTYPIC ANTIBODIES IN THE RAT IN-VITRO CHARACTERIZATION OF SPECIFICITY AND CORRELATION WITH IN-VIVO SPECIFIC SUPPRESSION OF CARDIAC ALLOGRAFT IMMUNE REACTION ACROSS MAJOR HISTOCOMPATIBILITY COMPLEX", SURGERY (ST LOUIS), vol. 108, no. 2, 1990, pages 431 - 441, XP009011104, ISSN: 0039-6060 *
ZHOU EN-MIN ET AL: "Comparison of Freund's adjuvant and TiterMax in inducing anti-idiotype to idiotypic antibodies against pseudorabies virus antigens.", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 48, no. 1-2, 1995, pages 113 - 122, XP002241974, ISSN: 0165-2427 *

Also Published As

Publication number Publication date
CA2449026A1 (en) 2002-12-05
NO20035282D0 (no) 2003-11-27
EP1399185A2 (de) 2004-03-24
JP2004532261A (ja) 2004-10-21
BR0210239A (pt) 2004-03-30
AT410637B (de) 2003-06-25
IL158950A0 (en) 2004-05-12
SK14662003A3 (sk) 2004-05-04
NO20035282L (no) 2003-11-27
PL367835A1 (en) 2005-03-07
CN1512895A (zh) 2004-07-14
HUP0400031A2 (hu) 2004-04-28
IL158950A (en) 2008-04-13
US20040151717A1 (en) 2004-08-05
ATA8602001A (de) 2002-11-15
HUP0400031A3 (en) 2006-03-28
MXPA03010829A (es) 2004-02-17
WO2002096455A2 (de) 2002-12-05
CZ20033273A3 (en) 2004-07-14
AU2002242447B2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
WO2021222935A3 (en) Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
WO2005061544A3 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
PL392964A1 (pl) Antygen reaktywny wobec surowicy hiperimmunologicznej zastosowanie tego antygenu do produkcji preparatu farmaceutycznego, fragment hiperimmunologiczny antygenu, epitopy pomocnicze antygenu, szczepionka zawierająca antygen reaktywny wobec surowicy hiperimmunologicznej, preparat zawierający przeciwciała, sposób wytwarzania tego preparatu, zastosowanie preparatu do leczenia infekcji gronkowcowych oraz sposób przesiewania
WO2002102829A3 (en) Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
HK1094167A1 (en) Monoclonal antibodies to hepatocyte growth factor
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
WO2003063772A3 (en) Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
WO2005002526A3 (en) Method and compositions for treatment of viral infections
HUP0302681A2 (hu) Protein antigének hősokk fehérjékhez való gerelyszerű hozzákötése
WO2003046007A3 (en) Treatment of micro-organism infection
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2002096455A3 (de) Verwendung von polyklonalen immunglobulinen als impfstoff
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
WO2004041864A3 (en) Passive hyperimmune antibody therapy in the treatment of anthrax
WO2002094881A3 (en) Monoclonal antibody neutralising cathepsin b activity and uses thereof
WO2001049319A8 (de) Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 158950

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002242447

Country of ref document: AU

Ref document number: 529700

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/A/2003/010829

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2021/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2449026

Country of ref document: CA

Ref document number: 14662003

Country of ref document: SK

Ref document number: 2002707990

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002592964

Country of ref document: JP

Ref document number: 028111214

Country of ref document: CN

Ref document number: PV2003-3273

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 091122002

Country of ref document: AT

WWE Wipo information: entry into national phase

Ref document number: 10478942

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002707990

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-3273

Country of ref document: CZ